Cargando…
Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer
Despite the clinical success of tamoxifen, its resistance remains a major challenge in breast cancer. Here we show that Aurora-A determines tamoxifen sensitivity by regulation of estrogen receptor (ER)α. Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivit...
Autores principales: | Zheng, XQ, Guo, JP, Yang, H, Kanai, M, He, LL, Li, YY, Koomen, JM., Minton, S., Gao, M, Ren, XB, Coppola, D, Cheng, JQ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002670/ https://www.ncbi.nlm.nih.gov/pubmed/24166501 http://dx.doi.org/10.1038/onc.2013.444 |
Ejemplares similares
-
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα
(+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023) -
TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021) -
Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression
por: Pan, Xiaohua, et al.
Publicado: (2022) -
Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERα expression
por: Li, Yuanyuan, et al.
Publicado: (2017) -
The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer
por: Liu, Shu-Shu, et al.
Publicado: (2020)